Messages in brief
Discontinued pharmaceuticals
Unless marketing authorization holders have made use of the legal provision (Section 94 c (10) of the Austrian Medicines Act) and submitted the…
PANGEA V and BASG: Dubious Internet Sources of Supply
The BMG, BMI, BMF and BASG participated in this year's action week. The operation took place this year from 25.09. to 02.10.2012. In total, more than…
Desmopressin (Nocutil, Minirin)
The active ingredient desmopressin (contained in various preparations) is approved for the treatment of primary enuresis nocturna, for the treatment…
Update: Ukrain (celandine extract)
Ukrain is a medicinal product made from celandine extracts produced by the pharmaceutical company Nowicky Pharma. The drug was advertised in the EU as…
Delimitation of live animals as medicinal products
In accordance with Section 1 (3b) of the Austrian Medicines Act, Federal Law Gazette No. 185/1983, as amended, the following official demarcation has…
New European pharmacovigilance legislation
The following innovations are planned throughout Europe:
Risk and risk managementAllmedicinal products carry known and unknown risks at the time of…
Use of combined oral contraceptives (COCs)
The occurrence of venous thromboembolic events (VTE) is a rare but long-known adverse effect of combined oral contraceptives (COCs), which is…
Anapen (Epinephrin)
Anapen (active ingredient: epinephrine) has been approved for the treatment of a state of shock (anaphylactic emergency) in some European member…
EMA makes safety data publicly available
As part of its transparency policy, the EMA has made data on adverse reaction reports publicly available at www.adrreports.eu since May 31, 2012. This…
